SCIENCE

1

[{"selector":"#anim-b7f3a1b6-270b-41b4-9151-378d35fc448f","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9331d7d4-31f2-4acf-8adb-11b5e850f149","keyframes":{"transform":["translate3d(0px, 819.51893%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-daacbbb8-a83d-43dd-8131-9b124f67d874","keyframes":{"opacity":[0,1]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f72984d8-2ba7-4ba3-9e65-d388a5a92f65","keyframes":{"transform":["translate3d(0px, 205.82440%, 0)","translate3d(0px, 0px, 0)"]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

2

[{"selector":"#anim-d60c1224-2c01-42de-b782-2e9a50dd9ab0","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9ee2296b-aa89-4174-8f3c-81f7c3e90e11","keyframes":{"transform":["translate3d(0px, 819.51893%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d9bca590-3f4c-42b5-a97f-c50919d25377","keyframes":{"opacity":[0,1]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-2ad29e75-0a6a-41b7-881d-6dc178448e1d","keyframes":{"transform":["translate3d(0px, 162.56191%, 0)","translate3d(0px, 0px, 0)"]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

3

[{"selector":"#anim-b90a0417-b55d-4988-99a6-205db0948d5a","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a00beabc-b918-406e-be24-b664749cd2b1","keyframes":{"transform":["translate3d(0px, 819.51893%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c8e6db37-04bf-4602-9a2c-dc79a827e81b","keyframes":{"opacity":[0,1]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c857f47c-f0ed-45b5-a06c-f0ad8844ab8d","keyframes":{"transform":["translate3d(0px, 162.56191%, 0)","translate3d(0px, 0px, 0)"]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

4

[{"selector":"#anim-624e939f-22ed-4b4f-b0f7-01f82a91f2a9","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-590b3f20-5cae-420e-8d21-077cd9225131","keyframes":{"transform":["translate3d(0px, 819.51893%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5603a2b3-578e-4e37-8ce9-3e60a1ffed51","keyframes":{"opacity":[0,1]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ce0cfcdb-4f64-49f9-8ed6-92dbf58ad3d5","keyframes":{"transform":["translate3d(0px, 205.82440%, 0)","translate3d(0px, 0px, 0)"]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

5

[{"selector":"#anim-b2767ead-b40d-447c-8a0c-b8d321a7524b","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f2ec734d-fa2d-4d56-9a68-ee38f0baba24","keyframes":{"transform":["translate3d(0px, 819.51893%, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a49c03bf-ebd7-4cb2-be14-7de22d77b01a","keyframes":{"opacity":[0,1]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-b716485f-ce2f-42d1-be37-70f5973b1df1","keyframes":{"transform":["translate3d(0px, 162.56191%, 0)","translate3d(0px, 0px, 0)"]},"delay":600,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}]

[{"selector":"#anim-0a7f2d57-9a77-4bd2-8a19-96d89ae989f2","keyframes":[{"transform":"scale(1)","offset":0},{"transform":"scale(1.5)","offset":0.33},{"transform":"scale(0.95)","offset":0.66},{"transform":"scale(1)","offset":1}],"delay":0,"duration":1450,"easing":"ease-in-out","fill":"both","iterations":1}] AI-designed drug enters clinical trials Read more about this here

[{"selector":"#anim-8a6b8d46-ddb7-4dfd-a2f3-c7181e7fee3f","keyframes":[{"transform":"scale(1)","offset":0},{"transform":"scale(1.5)","offset":0.33},{"transform":"scale(0.95)","offset":0.66},{"transform":"scale(1)","offset":1}],"delay":0,"duration":1450,"easing":"ease-in-out","fill":"both","iterations":1}] Click Here For more Science news click on the link below

SCIENCE

AI-designed drug enters clinical trials

1

AI-designed drug

A drug, the first to be designed and discovered completely with the help of AI, is now entering into phase 2 clinical trials.

2

IPF

This drug, which is developed by Hong Kong-based Insilico Medicine, is targeted at a rare chronic lung disease called idiopathic pulmonary fibrosis (IPF).

3

Process

Insilico Medicine first identified proteins linked to the IPF disease and then screened substances that could inhibit these proteins to develop the drug.

4

Phase 1 trials

The company has already completed the phase 1 trials of the IPF drug in New Zealand and China with "favorable results."

5

Phase 2 trials

The phase 2 clinical trials of the IPF drug will aim to evaluate the efficacy of the drug and estimate its safety profile. It will include 60 participants from China and US.